1C-UMN-
Mark Lebwohl, MD
Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, NY
Raptiva™
(efalizu...
2C-UMN-
Psoriasis
3C-UMN-
Psoriasis
4C-UMN-
Psoriasis
5C-UMN-
Psoriasis: Unmet Medical Need
• 4½ million Americans have psoriasis with at
least 10% of those patients having
mod...
6C-UMN-
Short Form 36 (SF-36) Health Survey
• Health status measurement tool that can
compare different disease states
• 8...
7C-UMN-
Lower scores reflect worse patient-reported outcomes
Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.
Physical...
8C-UMN-
Mental Component Summary Score
(n = 317)
60403020100
SF-36Score
50
Hypertension 52
Depression 35
Congestive Heart ...
9C-UMN-
Patients Dissatisfied with
Current Psoriasis Therapy
Krueger G, et al. Arch Dermatol. 2001;137:280-284.
78%
32%
0 ...
10C-UMN-
Drawbacks of Current Psoriasis Therapies
UVB Frequent visits
PUVA Frequent visits, skin
carcinoma, melanoma
Acitr...
11C-UMN-
Rotational Therapy
• All widely used therapies have shortcomings
• Major concerns with toxicities have resulted i...
12C-UMN-
Concerns from a Practitioner
• Concerns
– Safety of the current treatments for
moderate-to-severe plaque psoriasi...
13C-UMN-
65
26
9
0
20
40
60
80
≥ 50%
Reduction
in PASI
≥ 75%
Reduction
in PASI
Proportion
responding(%)
≥ 90%
Reduction
in...
14C-UMN-
Example: PASI-50 After 12 Weeks of Treatment
Day 84: PASI 6.8
(62% improvement)
Day 0: PASI 18.0
Study 2390, #350...
15C-UMN-
Summary
• Psoriasis is a chronic life-long disease
that causes significant disability
• Current treatments have l...
Upcoming SlideShare
Loading in...5
×

C-UMN- Mark Lebwohl, MD Chairman, Department of Dermatology

341

Published on

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
341
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • 01/29/15 08:38
  • 01/29/15 08:38
  • 01/29/15 08:38
    .
  • 01/29/15 08:38
  • 01/29/15 08:38
  • C-UMN- Mark Lebwohl, MD Chairman, Department of Dermatology

    1. 1. 1C-UMN- Mark Lebwohl, MD Chairman, Department of Dermatology Mount Sinai School of Medicine New York, NY Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need
    2. 2. 2C-UMN- Psoriasis
    3. 3. 3C-UMN- Psoriasis
    4. 4. 4C-UMN- Psoriasis
    5. 5. 5C-UMN- Psoriasis: Unmet Medical Need • 4½ million Americans have psoriasis with at least 10% of those patients having moderate-to-severe disease • About 500-600,000 of these patients are candidates for systemic therapy • People with moderate-to-severe disease reported a larger, negative impact on QOL • Majority of patients with moderate-to-severe psoriasis are not using the most aggressive treatments for their disease Koo JY. Dermatol Clinics 1996;14:485-96., NPF Survey
    6. 6. 6C-UMN- Short Form 36 (SF-36) Health Survey • Health status measurement tool that can compare different disease states • 8 domains • Assesses impact of disease and treatment on functional status and well-being • Physical Component Summary • Mental Component Summary Ware JE, et al. SF-36® Health Survey Manual and Interpretation Guide. The Health Institute;1993.
    7. 7. 7C-UMN- Lower scores reflect worse patient-reported outcomes Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407. Physical Component Summary Score (n = 317) 50454035302520151050 SF-36Score Psoriasis 41 Hypertension 44 Myocardial Infarction Congestive Heart Failure 35 Diabetes 42 Depression 45 Arthritis 43 Cancer 45 43 Impact of Psoriasis vs. Other Diseases on Patient-reported Physical Outcomes
    8. 8. 8C-UMN- Mental Component Summary Score (n = 317) 60403020100 SF-36Score 50 Hypertension 52 Depression 35 Congestive Heart Failure 50 Psoriasis 46 Myocardial Infarction 52 Arthritis 49 Diabetes 52 Cancer 49 Impact of Psoriasis vs. Other Diseases on Patient-reported Mental Outcomes Lower scores reflect worse patient-reported outcomes Rapp SR, et al. J Am Acad Dermatol. 1999;41:401-407.
    9. 9. 9C-UMN- Patients Dissatisfied with Current Psoriasis Therapy Krueger G, et al. Arch Dermatol. 2001;137:280-284. 78% 32% 0 10 20 30 40 50 60 70 80 90 100 Percentage of respondents Treatment not aggressive enough Frustrated with treatment
    10. 10. 10C-UMN- Drawbacks of Current Psoriasis Therapies UVB Frequent visits PUVA Frequent visits, skin carcinoma, melanoma Acitretin Teratogenic, inadequate as monotherapy Methotrexate Bone marrow toxicity, hepatotoxicity Cyclosporine Nephrotoxicity Alefacept Weekly office visits, slow onset
    11. 11. 11C-UMN- Rotational Therapy • All widely used therapies have shortcomings • Major concerns with toxicities have resulted in “rotational therapy” as a management approach
    12. 12. 12C-UMN- Concerns from a Practitioner • Concerns – Safety of the current treatments for moderate-to-severe plaque psoriasis • Needs – Need for safe, convenient and effective treatment option that reduces psoriasis – Need for a therapy safe enough to give over the long term – Need for rapid acting therapy
    13. 13. 13C-UMN- 65 26 9 0 20 40 60 80 ≥ 50% Reduction in PASI ≥ 75% Reduction in PASI Proportion responding(%) ≥ 90% Reduction in PASI Callis et al. Presented at: 63rd Annual Meeting of the Society for Investigative Dermatology; May 15-18, 2002, Los Angeles, CA n = 23 Efficacy of Methotrexate Treatment (15–30 mg/wk): PASI Response at Week 24
    14. 14. 14C-UMN- Example: PASI-50 After 12 Weeks of Treatment Day 84: PASI 6.8 (62% improvement) Day 0: PASI 18.0 Study 2390, #35006
    15. 15. 15C-UMN- Summary • Psoriasis is a chronic life-long disease that causes significant disability • Current treatments have limitations • Need a safe and effective therapy for long-term use
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×